02:54 PM EST, 01/21/2025 (MT Newswires) -- Atara Biotherapeutics ( ATRA ) shares were down almost 10% Tuesday after its active investigational new drug applications were placed on clinical hold by the US Food and Drug Administration.

The INDs cover Ebvallo, a treatment for patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease, and the ATA3219 drug product for non-Hodgkin's lymphoma and systemic lupus erythematosus, the company said.

The clinical hold for both programs comes amid "compliance issues" at a third-party manufacturing facility, Atara said.

Atara said new patient recruitment for both programs have been suspended while participants in the clinical trials with potential clinical benefit may continue receiving treatment according to established study protocols.

Price: 5.95, Change: -0.63, Percent Change: -9.51